DermTech saw the highest growth of 1.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of DermTech‘s patent filings and grants. Buy the databook here.
DermTech has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 100% grants. The United States(US), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where DermTech is filings its patents. Among the top granted patent authorities, DermTech has 100% of its grants in United States(US).
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for DermTech
Patents related to rare diseases and genomics lead DermTech's portfolio
DermTech has the highest number of patents in rare diseases followed by, genomics and immuno-oncology. For rare diseases, nearly 50% of patents were filed and 50% of patents were granted in Q2 2024.
General surgery devices related patents lead DermTech portfolio followed by actinic (solar) keratosis, and dermatological disorders
DermTech has highest number of patents in general surgery devices followed by actinic (solar) keratosis, dermatological disorders, atopic dermatitis (atopic eczema), and vitiligo.
For comprehensive analysis of DermTech's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.